Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

The lawsuit claims GlaxoSmithKline replaced Flovent with ... citing the Arizona Consumer Fraud Act, says that the London-based multinational company was motivated by greed when it discontinued ...

Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Lacalle Pou “welcomed GSK's announcement of the opening of one ... The UK “encouraged exploring the cross-issuance of this bond in London to access the ample global capital funds present ...

The Department of Homeland Security is asking for the Internal Revenue Service to help crack down on immigration, according ...

This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...

GSK’s shares rose as much as 4.5 per cent in early trading in London. They’ve been held back by concern over the pipeline and what is seen as few near-term catalysts, and were down 17 per cent over ...

Copyright 2025 Alliance News Ltd. All Rights Reserved.

GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...